ALK and non-small cell lung carcinoma: Crizotinib, a 3-benzyloxy-2-aminopyridine derivative that targets the ATP-binding site of ALK, was approved for clinical use in patients with ALK-positive NSCLC and rapidly emerged as a breakthrough therapy, significantly improving PFS and overall response rates.